Liquidia Technologies (LQDA) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Liquidia Technologies (NASDAQ:LQDA) from a hold rating to a sell rating in a research report report published on Wednesday.

According to Zacks, “Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company’s product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States. “

Several other brokerages have also recently issued reports on LQDA. Cowen started coverage on shares of Liquidia Technologies in a research note on Monday, August 20th. They set an outperform rating and a $40.00 price objective for the company. Wedbush boosted their price objective on shares of Liquidia Technologies from $26.00 to $28.00 and gave the company a buy rating in a research note on Thursday, November 1st. Jefferies Financial Group started coverage on shares of Liquidia Technologies in a research note on Monday, August 20th. They set a buy rating and a $22.00 price objective for the company. Finally, Needham & Company LLC set a $32.00 price objective on shares of Liquidia Technologies and gave the company a buy rating in a research note on Wednesday, October 31st. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $31.75.

LQDA stock traded up $0.85 during midday trading on Wednesday, hitting $19.08. The stock had a trading volume of 24,759 shares, compared to its average volume of 52,688. The company has a quick ratio of 6.27, a current ratio of 6.27 and a debt-to-equity ratio of 0.40. Liquidia Technologies has a 12-month low of $10.52 and a 12-month high of $38.46.

Liquidia Technologies (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, October 31st. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.26). The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.03 million. On average, sell-side analysts anticipate that Liquidia Technologies will post -5.44 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in LQDA. BlackRock Inc. purchased a new stake in shares of Liquidia Technologies during the 3rd quarter valued at $5,924,000. FMR LLC purchased a new stake in shares of Liquidia Technologies during the 3rd quarter valued at $6,729,000. Finally, Dean Capital Investments Management LLC purchased a new stake in shares of Liquidia Technologies during the 3rd quarter valued at $1,483,000. 0.01% of the stock is owned by institutional investors.

About Liquidia Technologies

Liquidia Technologies, Inc is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies.

Further Reading: Compound Interest and Why It Matters When Investing

Get a free copy of the Zacks research report on Liquidia Technologies (LQDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply